A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

BACKGROUND: Spartalizumab is a humanized IgG4κ monoclonal antibody that binds programmed death-1 (PD-1) and blocks its interaction with PD-L1 and PD-L2. This phase 1/2 study was designed to assess the safety, pharmacokinetics, and preliminary efficacy of spartalizumab in patients with advanced or me...

Descripción completa

Detalles Bibliográficos
Autores principales: Naing, Aung, Gainor, Justin F, Gelderblom, Hans, Forde, Patrick M, Butler, Marcus O, Lin, Chia-Chi, Sharma, Sunil, Ochoa de Olza, Maria, Varga, Andrea, Taylor, Matthew, Schellens, Jan H M, Wu, Hongqian, Sun, Haiying, Silva, Antonio P, Faris, Jason, Mataraza, Jennifer, Cameron, Scott, Bauer, Todd M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073791/
https://www.ncbi.nlm.nih.gov/pubmed/32179633
http://dx.doi.org/10.1136/jitc-2020-000530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073791/
https://www.ncbi.nlm.nih.gov/pubmed/32179633
http://dx.doi.org/10.1136/jitc-2020-000530

Ejemplares similares